ACVR2B is an activin receptor that binds to GDFs and activins, activating type I receptors such as activin receptor-like kinases (ALK) ALK4 and ALK5, thus stimulating the activation of downstream molecule SMAD2/3. SMADSs regulate a number of myogenic genes, such as myoD, myogenin, and Myf5, that are involved in cellular hypertrophy, proliferation, or differentiation. Noncanonical ACVR2B pathways have also been shown to regulate MAP kinases. ACVR2B-BMP3 interaction plays a key role in BMP-mediated osteoblasts (OBL) differentiation by demonstrating that knockdown of endogenous ACVR2B diminishes the inhibitory effect of BMP3 on osteoprogenitor cells.
The vectors expressing anti-ACVR2B antibody were constructed as follows: immunizing an animal with A synthesized peptide derived from human Activin Receptor Type IIB, isolating the positive splenocyte and extracting RNA, obtaining DNA by reverse transcription, sequencing and screening ACVR2B antibody gene, and amplifying heavy and light chain sequence by PCR and cloning them into plasma vectors. After that, the vector clones were transfected into the mammalian cells for production. The product is the recombinant ACVR2B antibody. Recombinant ACVR2B antibody in the culture medium was purified using Affinity-chromatography. It can react with ACVR2B protein from Human and is used in the ELISA, IHC.